OMERS ADMINISTRATION Corp Has $6.21 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

OMERS ADMINISTRATION Corp lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 38.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 86,178 shares of the medical equipment provider’s stock after selling 54,036 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Hologic were worth $6,213,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Venturi Wealth Management LLC increased its stake in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares during the period. Smithfield Trust Co grew its stake in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 400 shares during the period. Finally, Sound Income Strategies LLC bought a new stake in Hologic in the 4th quarter valued at about $60,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Buying and Selling

In related news, Director Martin D. Madaus acquired 5,445 shares of the firm’s stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares of the company’s stock, valued at approximately $300,781.80. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.88% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several recent research reports. Argus lowered Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. StockNews.com lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Evercore ISI decreased their price target on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating for the company in a research note on Friday, May 2nd. Finally, Morgan Stanley lowered their price objective on shares of Hologic from $77.00 to $65.00 and set an “equal weight” rating on the stock in a report on Monday, May 5th. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and an average target price of $77.42.

Hologic Stock Performance

NASDAQ HOLX opened at $57.12 on Wednesday. The company has a fifty day moving average price of $59.26 and a 200-day moving average price of $67.94. The firm has a market cap of $12.73 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 2.14 and a beta of 0.54. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.03 EPS. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.